Which pathway do you prioritize targeting next in a patient with HFpEF who continues to experience hospitalizations for worsening heart failure despite maximally tolerated SGLT2i and finerenone?

Which pathway do you prioritize targeting next in a patient with HFpEF who continues to experience hospitalizations for worsening heart failure despite maximally tolerated SGLT2i and finerenone?

• Further neurohormonal blockade targeting persistent aldosterone excess
• Intensified volume and hemodynamic management
• Addressing underlying metabolic or inflammatory drivers
• I focus on non-pharmacologic interventions
• Other